Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janssen Pharmaceuticals Inc.

www.janssenpharmaceuticalsinc.com

Latest From Janssen Pharmaceuticals Inc.

Generic Drugs: ‘Competitive’ Exclusivity Benefited Few Sponsors But Is Increasingly Popular

The six months of additional exclusivity from US FDA’s CGT program appears to have kept some generic sponsors from the market, and didn’t even prompt others to enter quickly, but use of the competitive generic exclusivity program continues to grow.

Generic Drugs Intellectual Property

Part D Cost Sharing Cap May Have Broadest Benefit For Jakafi, Revlimid, Pomalyst, Imbruvica Users

A cap set at $2,000 would help nearly 1 million more seniors than a cap set at $3,100, according to new study by Kaiser Family Foundation. Either competing legislative proposal would probably be welcomed by pharma industry as way to defuse pricing debate.

Medicare Legislation

NICE Reverses English Funding Rejection For Erleada After Janssen Drops Price

The androgen receptor inhibitor Erleada is now considered to be a cost-effective use of National Health Service resources.

Cancer United Kingdom

Cautious Optimism As Genentech/AC Immune’s Anti-Tau Antibody Slows Cognitive Decline

Semorinemab met only the cognition co-primary endpoint in the Phase II LAURIET trial in mild-to-moderate Alzheimer’s patients and missed all secondary endpoints, but some firsts were achieved in the top-line readout.

Clinical Trials Neurology
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register